Osteonecrosis of the jaw: a rare and devastating side effect of bisphosphonates
- 1 December 2009
- journal article
- review article
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 85 (1010) , 674-677
Abstract
Evidence has emerged that bisphosphonate use in cancer patients is associated with osteonecrosis of the jaw. This form of osteonecrosis has been termed bisphosphonate induced osteonecrosis of the jaw (BIONJ). BIONJ is commonly precipitated by a tooth extraction in patients treated with long term, potent, high dose intravenous bisphosphonates for the management of myeloma, breast or prostate cancer. The overall prevalence of BIONJ is about 5% in patients with these malignancies. Current evidence shows that the risk of BIONJ in non-cancerous patients, such as those with osteoporosis, is very low and appears to be comparable with that of the general population. Prescribing physicians need to encourage cancer patients to see their dentists before the initiation of bisphosphonate treatment, and regularly thereafter.Keywords
This publication has 22 references indexed in Scilit:
- Zoledronate, Smoking, and Obesity Are Strong Risk Factors for Osteonecrosis of the Jaw: A Case-Control StudyJournal of Oral and Maxillofacial Surgery, 2008
- Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panelAnnals of Oncology, 2007
- Imaging Findings of Bisphosphonate-Associated Osteonecrosis of the JawsAmerican Journal of Neuroradiology, 2007
- A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myelomaLeukemia, 2007
- Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk FactorsJournal of Clinical Oncology, 2006
- Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk FactorsJournal of Clinical Oncology, 2005
- Osteonecrosis of the Jaw and BisphosphonatesNew England Journal of Medicine, 2005
- Bisphosphonate‐associated osteonecrosis of mandibular and maxillary boneCancer, 2005
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2002
- Esophagitis Associated with the Use of AlendronateNew England Journal of Medicine, 1996